CompletedNot Applicable

T Central Memory Cells in Early Localized Non-Segmental Vitiligo

Egypt22 participantsStarted 2023-02-01

Plain-language summary

Assessing the level of circulating TCMs (cluster of differentiation (CD) 8+, CD3+,C- chemokine receptor (CCR)7, cluster of differentiation 45 receptor (CD45R) cells) in early localized vitiligo cases prior to treatment and after treatment in comparison to healthy controls. This, in turn, would provide insights regarding the role of TCMs in vitiligo and the role of early treatment in halting disease progression and autoimmune memory formation that accounts for high recurrence rate of vitiligo

Who can participate

Age range12 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Subjects with vitiligo localized to one anatomical area, of ≤ 6 months' duration Exclusion Criteria: * Patients who received treatment of any type (topical or systemic) within the last 3 months

What they're measuring

comparing level of circulating central memory T cells (TCM) in early localized vitiligo cases to healthy controls

Timeframe: 6 months

percent change in the level of circulating central memory T cells (TCM) in early localized vitiligo cases after treatment

Timeframe: 6 months

comparing percent change in the level of circulating central memory T cells (TCM) in early localized vitiligo cases after treatment in those receiving systemic treatment to those receiving only topical treatment

Timeframe: 6 months

Trial details

NCT IDNCT05706636

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-01

View on ClinicalTrials.gov More Vitiligo trials